Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and commercialize ...

Weight-loss drugs draw thousands of lawsuits alleging serious harm Economist warns coming financial crisis will make 2008 look like 'Sunday school picnic' Elon Musk says Tesla ending Models S and X ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

The new Apple Creator Studio bundles the company's flagship creative software in a monthly subscription package for the first time. It's a great value, assuming you haven't bought most of them ...

Twenty years after the introduction of the theory, we revisit what it does—and doesn’t—explain. by Clayton M. Christensen, Michael E. Raynor and Rory McDonald Please enjoy this HBR Classic. Clayton M.

Ryan Eichler holds a B.S.B.A with a concentration in Finance from Boston University. He has held positions in, and has deep experience with, expense auditing, personal finance, real estate, as well as ...